Kowa Company, Ltd.

Kowa Company, Ltd., is a privately held, multinational company headquartered in Nagoya, Japan. Established in 1894, Kowa is actively engaged in various manufacturing and trading activities in the fields of pharmaceuticals, textile, machinery, construction materials, chemicals, commodities and hospitality. Kowa's pharmaceutical division is focused 
on research and development for cardiovascular therapeutics (dyslipidemia, type 2 diabetes and atherosclerosis), ophthalmology and anti-inflammatory agents. The company’s flagship product, LIVALO^® (pitavastatin), is approved in 45 countries around the world.

Kowa has a strong US footprint focused on discovery, research and development, and commercialization of effective healthcare solutions.

Kowa Pharmaceuticals America

• Commercializing safe and effective healthcare products in the United States

Kowa Research Institute

• Spearheading the clinical development of Kowa Company’s new drugs in the United States

Kowa Science Institute

• Exploring new approaches to targeting discoveries that can speed up the translation of basic science findings into the clinic as new therapies

Established in 2008, Kowa Pharmaceuticals America is part of Kowa Company Ltd., and is committed to continuing the development and commercialization of safe and effective healthcare solutions for our current and near-term portfolio of pharmaceutical products and business development activities.

We are:

• A pharma company with a history of doing things the right way while elevating the value of brands from all over the US
• Powered by a strong history of compliance and the desire to ensure patients are getting the best treatment options available
• Proud of our expertise in training sales representatives, company leaders, and everyone in between to overcome day-to-day and complex challenges
• Focused on results